{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:12:26Z","timestamp":1789791146934,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81773303"],"award-info":[{"award-number":["81773303"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572993"],"award-info":[{"award-number":["81572993"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830005"],"award-info":[{"award-number":["81830005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Initiative for Innovative Medicine","award":["2016-I2M-1-007"],"award-info":[{"award-number":["2016-I2M-1-007"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["2016-I2M-3-013"],"award-info":[{"award-number":["2016-I2M-3-013"]}]},{"name":"National Precision Medicine Special Fund","award":["2017YFC0909800"],"award-info":[{"award-number":["2017YFC0909800"]}]},{"name":"CIFMS","award":["2017-I2M-1-005"],"award-info":[{"award-number":["2017-I2M-1-005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13045-019-0723-8","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T05:05:55Z","timestamp":1556168755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells"],"prefix":"10.1186","volume":"12","author":[{"given":"Yuanyuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangzhen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengshang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangfei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuewen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,25]]},"reference":[{"issue":"6","key":"723_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"723_CR2","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast Cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"723_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938\u201348.","journal-title":"N Engl J Med"},{"issue":"18","key":"723_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767\u201378.","journal-title":"N Engl J Med"},{"issue":"328","key":"723_CR5","doi-asserted-by":"publisher","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv324.","journal-title":"Sci Transl Med"},{"issue":"6","key":"723_CR6","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.cell.2015.08.038","volume":"162","author":"DR Littman","year":"2015","unstructured":"Littman DR. Releasing the brakes on cancer immunotherapy. Cell. 2015;162(6):1186\u201390.","journal-title":"Cell"},{"issue":"6","key":"723_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.it.2016.03.010","volume":"37","author":"LE Klevorn","year":"2016","unstructured":"Klevorn LE, Teague RM. Adapting cancer immunotherapy models for the real world. Trends Immunol. 2016;37(6):354\u201363.","journal-title":"Trends Immunol"},{"key":"723_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrclinonc.2015.237","volume":"13","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Hodi FS. Immune-checkpoint blockade \u2014 durable cancer control. Nat Rev Clin Oncol. 2016;13:77.","journal-title":"Nat Rev Clin Oncol"},{"key":"723_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nrclinonc.2016.170","volume":"13","author":"D Killock","year":"2016","unstructured":"Killock D. Anti-PD-1 therapy in the frontline. Nat Rev Clin Oncol. 2016;13:715.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10031","key":"723_CR10","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"issue":"6230","key":"723_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56.","journal-title":"Science"},{"issue":"11","key":"723_CR12","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MWL Teng","year":"2015","unstructured":"Teng MWL, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139.","journal-title":"Cancer Res"},{"issue":"47","key":"723_CR13","doi-asserted-by":"publisher","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","volume":"112","author":"RL Maute","year":"2015","unstructured":"Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci. 2015;112(47):E6506.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"723_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-017-0522-z","volume":"10","author":"S Yu","year":"2017","unstructured":"Yu S, Li A, Liu Q, Yuan X, Xu H, Jiao D, Pestell RG, Han X, Wu K. Recent advances of bispecific antibodies in solid tumors. J Hematol Oncol. 2017;10(1):155.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"723_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-017-0091-4","volume":"6","author":"S Yu","year":"2017","unstructured":"Yu S, Liu Q, Han X, Qin S, Zhao W, Li A, Wu K. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Experimental Hematology & Oncology. 2017;6(1):31.","journal-title":"Experimental Hematology & Oncology"},{"issue":"7","key":"723_CR16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1078-0432.CCR-13-2116","volume":"20","author":"A Marabelle","year":"2014","unstructured":"Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014;20(7):1747.","journal-title":"Clin Cancer Res"},{"issue":"429","key":"723_CR17","doi-asserted-by":"publisher","first-page":"eaan3682","DOI":"10.1126\/scitranslmed.aan3682","volume":"10","author":"Chao Wang","year":"2018","unstructured":"Wang C, Wang J, Zhang X, Yu S, Wen D, Hu Q, Ye Y, Bomba H, Hu X, Liu Z, et al. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci Transl Med. 2018;10(429).","journal-title":"Science Translational Medicine"},{"issue":"433","key":"723_CR18","doi-asserted-by":"publisher","first-page":"eaar1916","DOI":"10.1126\/scitranslmed.aar1916","volume":"10","author":"Chun Gwon Park","year":"2018","unstructured":"Park CG, Hartl CA, Schmid D, Carmona EM, Kim H-J, Goldberg MS. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci Transl Med. 2018;10(433).","journal-title":"Science Translational Medicine"},{"issue":"5","key":"723_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1158\/0008-5472.CAN-12-3343","volume":"73","author":"B Kwong","year":"2013","unstructured":"Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ. Localized immunotherapy via liposome-anchored anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res. 2013;73(5):1547.","journal-title":"Cancer Res"},{"issue":"7","key":"723_CR20","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/stem.81","volume":"27","author":"H Wang","year":"2009","unstructured":"Wang H, Cao F, De A, Cao Y, Contag C, Gambhir SS, Wu JC, Chen X. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells. 2009;27(7):1548\u201358.","journal-title":"Stem Cells"},{"issue":"6","key":"723_CR21","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/stem.645","volume":"29","author":"MR Reagan","year":"2011","unstructured":"Reagan MR, Kaplan DL. Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells. 2011;29(6):920\u20137.","journal-title":"Stem Cells"},{"issue":"1","key":"723_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1741-7015-9-52","volume":"9","author":"A Trounson","year":"2011","unstructured":"Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med. 2011;9(1):52.","journal-title":"BMC Med"},{"key":"723_CR23","first-page":"1","volume":"2013","author":"Linan Liu","year":"2013","unstructured":"Liu L, Eckert MA, Riazifar H, Kang D-K, Agalliu D, Zhao W. From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier? Stem Cells Int. 2013;2013:\u2013435093.","journal-title":"Stem Cells International"},{"issue":"32","key":"723_CR24","doi-asserted-by":"crossref","first-page":"51815","DOI":"10.18632\/oncotarget.10122","volume":"7","author":"Z Li","year":"2016","unstructured":"Li Z, Ye Z, Zhang X, Zhang Q, Fan D, Zhang Y, Luo HR, Yuan X, Li Z, Xiong D. E1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice. Oncotarget. 2016;7(32):51815\u201328.","journal-title":"Oncotarget"},{"key":"723_CR25","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726.","journal-title":"Nat Rev Immunol"},{"key":"723_CR26","unstructured":"Li Z, Fan D, Xiong D: Mesenchymal stem cells as delivery vectors for anti-tumor therapy. In:Stem cell investigation. vol. 2; 2015: 6."},{"issue":"12","key":"723_CR27","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.1073\/pnas.0806647106","volume":"106","author":"LS Sasportas","year":"2009","unstructured":"Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JAJM, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci. 2009;106(12):4822.","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"723_CR28","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1158\/0008-5472.CAN-08-4698","volume":"69","author":"MR Loebinger","year":"2009","unstructured":"Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009;69(10):4134.","journal-title":"Cancer Res"},{"issue":"1","key":"723_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.canlet.2016.07.019","volume":"381","author":"X Yuan","year":"2016","unstructured":"Yuan X, Zhang Q, Li Z, Zhang X, Bao S, Fan D, Ru Y, Dong S, Zhang Y, Zhang Y, et al. Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically. Cancer Lett. 2016;381(1):85\u201395.","journal-title":"Cancer Lett"},{"issue":"7","key":"723_CR30","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/ijc.30846","volume":"141","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Yuan X-F, Lu Y, Li Z-Z, Bao S-Q, Zhang X-L, Yang Y-Y, Fan D-M, Zhang Y-Z, Wu C-X, et al. Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells. Int J Cancer. 2017;141(7):1445\u201357.","journal-title":"Int J Cancer"},{"key":"723_CR31","unstructured":"Ma L, Feng X-y, Cui B-l, Law F, Jiang X-w, Yang L-Y, Xie Q-D, Huang T: Human umbilical cord Wharton\u2019s jelly-derived mesenchymal stem cells differentiation into nerve-like cells, vol. 118; 2006."},{"issue":"9","key":"723_CR32","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1016\/j.biomaterials.2013.12.037","volume":"35","author":"C Yan","year":"2014","unstructured":"Yan C, Yang M, Li Z, Li S, Hu X, Fan D, Zhang Y, Wang J, Xiong D. Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter. Biomaterials. 2014;35(9):3035\u201343.","journal-title":"Biomaterials"},{"issue":"400","key":"723_CR33","doi-asserted-by":"publisher","first-page":"eaan2966","DOI":"10.1126\/scitranslmed.aan2966","volume":"9","author":"Linan Liu","year":"2017","unstructured":"Liu L, Zhang SX, Liao W, Farhoodi HP, Wong CW, Chen CC, S\u00e9galiny AI, Chacko JV, Nguyen LP, Lu M, et al. Mechanoresponsive stem cells to target cancer metastases through biophysical cues. Sci Transl Med. 2017;9(400).","journal-title":"Science Translational Medicine"},{"issue":"6","key":"723_CR34","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00262-015-1671-y","volume":"64","author":"T Osada","year":"2015","unstructured":"Osada T, Patel SP, Hammond SA, Osada K, Morse MA, Lyerly HK. CEA\/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother. 2015;64(6):677\u201388.","journal-title":"Cancer Immunol Immunother"},{"key":"723_CR35","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","volume":"30","author":"C Krupka","year":"2015","unstructured":"Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, K\u00f6hnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, et al. Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2015;30:484.","journal-title":"Leukemia"},{"issue":"21","key":"723_CR36","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543.","journal-title":"Mol Cell Biol"},{"issue":"23","key":"723_CR37","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1089\/scd.2013.0249","volume":"22","author":"K Mandel","year":"2013","unstructured":"Mandel K, Yang Y, Schambach A, Glage S, Otte A, Hass R. Mesenchymal stem cells directly interact with breast cancer cells and promote tumor cell growth in vitro and in vivo. Stem Cells Dev. 2013;22(23):3114\u201327.","journal-title":"Stem Cells Dev"},{"issue":"3","key":"723_CR38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.stem.2009.02.001","volume":"4","author":"JM Karp","year":"2009","unstructured":"Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206\u201316.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"723_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1158\/1078-0432.CCR-11-2701","volume":"19","author":"F Andre","year":"2013","unstructured":"Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2013;19(1):28.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"723_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, Loibl S, Noske A, Roller M, M\u00fcller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105\u201313.","journal-title":"J Clin Oncol"},{"issue":"10","key":"723_CR41","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/cncr.31272","volume":"124","author":"MJ Kwa","year":"2018","unstructured":"Kwa MJ, Adams S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here. Cancer. 2018;124(10):2086\u2013103.","journal-title":"Cancer"},{"key":"723_CR42","doi-asserted-by":"crossref","unstructured":"Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol. 2018:mdy399\u20139.","DOI":"10.1093\/annonc\/mdy399"},{"issue":"4","key":"723_CR43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","volume":"33","author":"RH Vonderheide","year":"2018","unstructured":"Vonderheide RH. The immune revolution: a case for priming, not checkpoint. Cancer Cell. 2018;33(4):563\u20139.","journal-title":"Cancer Cell"},{"issue":"1","key":"723_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-017-0397-z","volume":"10","author":"X Zhang","year":"2017","unstructured":"Zhang X, Yang Y, Zhang L, Lu Y, Zhang Q, Fan D, Zhang Y, Zhang Y, Ye Z, Xiong D. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3\/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan. J Hematol Oncol. 2017;10(1):56.","journal-title":"J Hematol Oncol"},{"key":"723_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14572","volume":"8","author":"J Lau","year":"2017","unstructured":"Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, Sanders L, Koeppen H, Caplazi P, McBride J, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:14572.","journal-title":"Nat Commun"},{"issue":"2","key":"723_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","volume":"5","author":"T Noguchi","year":"2017","unstructured":"Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunology Research. 2017;5(2):106.","journal-title":"Cancer Immunology Research"},{"issue":"43","key":"723_CR47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1206653109","volume":"109","author":"CP El-Haibi","year":"2012","unstructured":"El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, Csizmadia E, Mariani O, Zhu C, Campagne A, et al. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci. 2012;109(43):17460.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"723_CR48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","volume":"36","author":"FL Graham","year":"1977","unstructured":"Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36(1):59\u201372.","journal-title":"J Gen Virol"},{"issue":"5","key":"723_CR49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.molmed.2010.02.005","volume":"16","author":"J Ankrum","year":"2010","unstructured":"Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med. 2010;16(5):203\u20139.","journal-title":"Trends Mol Med"},{"issue":"5","key":"723_CR50","doi-asserted-by":"publisher","first-page":"651","DOI":"10.18632\/oncotarget.1040","volume":"4","author":"IA Droujinine","year":"2013","unstructured":"Droujinine IA, Eckert MA, Zhao W. To grab the stroma by the horns: from biology to cancer therapy with mesenchymal stem cells. Oncotarget. 2013;4(5):651\u201364.","journal-title":"Oncotarget"},{"key":"723_CR51","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"723_CR52","doi-asserted-by":"publisher","first-page":"E1239","DOI":"10.1073\/pnas.1718197115","volume":"115","author":"D Samanta","year":"2018","unstructured":"Samanta D, Park Y, Ni X, Li H, Zahnow CA, Gabrielson E, Pan F, Semenza GL. Chemotherapy induces enrichment of CD47+\/CD73+\/ PDL1+ immune evasive triple-negative breast cancer cells. Proc Natl Acad Sci. 2018;115(6):E1239.","journal-title":"Proc Natl Acad Sci"},{"issue":"6280","key":"723_CR53","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463.","journal-title":"Science"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0723-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-019-0723-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0723-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T16:58:32Z","timestamp":1607360312000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-019-0723-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,25]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1186\/s13045-019-0723-8","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,25]]},"assertion":[{"value":"2 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were performed in accordance with guidelines under the Animal Ethics Committee of the Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"46"}}